Factors Associated with Delirium Among Survivors of Acute Respiratory Distress Syndrome: a Nationwide Cohort Study
Overview
Authors
Affiliations
Background: The prevalence of delirium, its associated factors, and its impact on long-term mortality among survivors of acute respiratory distress syndrome (ARDS) is unclear.
Methods: Since this was a population-based study, data were extracted from the National Health Insurance database in South Korea. All adults who were admitted to intensive care units with a diagnosis of ARDS between January 1, 2010, and December 31, 2019, and who survived for ≥ 60 days were included. The International Statistical Classification of Diseases and Related Health Problems, tenth revision code of delirium (F05) was used to extract delirium cases during hospitalization.
Results: A total of 6809 ARDS survivors were included in the analysis, and 319 patients (4.7%) were diagnosed with delirium during hospitalization. In the multivariable logistic regression analysis after covariate adjustment, male sex (odds ratio [OR] 1.60, 95% confidence interval [CI] 1.23, 2.08; P < 0.001), longer duration of hospitalization (OR 1.02, 95% CI 1.01, 1.03; P < 0.001), neuromuscular blockade use (OR 1.50, 95% CI 1.12, 2.01; P = 0.006), benzodiazepine (OR 1.55, 95% CI 1.13, 2.13; P = 0.007) and propofol (OR 1.48, 95% CI 1.01, 2.17; P = 0.046) continuous infusion, and concurrent depression (OR 1.31, 95% CI 1.01, 1.71; P = 0.044) were associated with a higher prevalence of delirium among ARDS survivors. In the multivariable Cox regression analysis after adjustment for covariates, the occurrence of delirium was not significantly associated with 1-year all-cause mortality, when compared to the other survivors who did not develop delirium (hazard ratio: 0.85, 95% CI 1.01, 1.71; P = 0.044).
Conclusions: In South Korea, 4.7% of ARDS survivors were diagnosed with delirium during hospitalization in South Korea. Some factors were potential risk factors for the development of delirium, but the occurrence of delirium might not affect 1-year all-cause mortality among ARDS survivors.
Scott L, Winzey K, Moreira D, Bresee C, Vit J, Tourtellotte W J Neuroinflammation. 2024; 21(1):270.
PMID: 39434161 PMC: 11495074. DOI: 10.1186/s12974-024-03260-y.
Zhu S, Liu S, Li L, Xing H, Xia M, Dong G Front Med (Lausanne). 2024; 11:1412172.
PMID: 39386749 PMC: 11461200. DOI: 10.3389/fmed.2024.1412172.
Sun P, Fanning J, Peeler A, Shou B, Lindsley J, Caturegli G Front Med (Lausanne). 2023; 10:1172063.
PMID: 37305142 PMC: 10248255. DOI: 10.3389/fmed.2023.1172063.